Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous...

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Many multiple sclerosis (MS) patients have suboptimal disease control despite current disease-modifying therapies (DMTs).
• Identifying effective treatments for these patients is crucial for improving outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of ocrelizumab (OCR) in patients with relapsing-remitting MS (RRMS).
• Specifically assessed patients who showed a suboptimal response to prior DMTs.

Main Methods:

• Enrolled RRMS patients with suboptimal responses (relapse and/or lesion activity) after at least 6 months on another DMT.
• Administered OCR 600 mg intravenously every 24 weeks.
• Primary outcome: No Evidence of Disease Activity (NEDA), defined by absence of relapse, disability progression, and MRI lesion activity.

Main Results:

• 48.1% of patients in the modified intention-to-treat (mITT) population achieved NEDA over 96 weeks.
• High percentages of patients were free from protocol-defined relapse (89.6%), confirmed disability progression (89.6%), and T1 Gd-enhancing lesions (95.5%).
• Safety profile was consistent with previous pivotal trial findings.

Conclusions:

• Ocrelizumab demonstrated consistent efficacy in managing both clinical and MRI-assessed disease activity in RRMS patients with prior suboptimal DMT response.
• No new safety signals were identified, supporting OCR's use in this patient population.